Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Double-blind, controlled, multicenter study of indobufen versus placebo in patients with intermittent claudication

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effect of revascularization on lower extremity muscle function in combined type 2 diabetes and critical limb threatening ischemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mitochondrial dysfunction in calf muscles of patients with combined peripheral arterial disease and diabetes type 2

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Deep venous thrombosis of the upper extremity. A review

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Does patency after a vein collar and PTFE-bypass depend on sex and age? Re-analysis of a randomised trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Decreased syntheses of tissue plasminogen activator antigen in users of oral contraceptives

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Retrograde femoral angioplasty: a new technique

    Research output: Contribution to journalJournal articleResearchpeer-review

  • K H Tönnesen
  • P Albuquerque
  • G Baitsch
  • A Gomez Alonso
  • F Ibanez
  • R C Kester
  • S Leveson
  • P Poredos
View graph of relations
The objective of the study was to evaluate the efficacy and safety of indobufen compared with placebo in the treatment of moderately severe intermittent claudication. The study consisted of a four-week single-blind, placebo-controlled run-in phase, followed by a six-month double-blind randomized treatment period. A total of 302 patients were allocated to treatment with either placebo (154 patients) or indobufen (148) 200 mg twice daily. The results of the overall intention-to-treat analysis of the study population showed statistically significant superiority of indobufen over placebo after six months for both the initial (ICD) and absolute claudication distances (ACD). The ICD before treatment with indobufen or placebo averaged 137.9 +/- 68.2 and 136.6 +/- 63.2 m (mean +/- SD), respectively. After six months' treatment with active drug or placebo, this parameter reached 227.9 +/- 174.4 and 153.1 +/- 86.8 m (mean +/- SD), respectively (p <0.01). Similar results were obtained on ACD. The reduction of lower limb symptoms also suggested a greater clinical benefit in the indobufen-treated patients. There was no significant change in either group in the ankle/arm pressure ratio at the end of treatment. Adverse events of any type were reported by 18 patients (12.2%) in the indobufen group and by 11 patients (7.2%) in the placebo group. The mechanism whereby the drug is effective in this clinical condition could be related to both its antiplatelet and hemorheologic effects.
Original languageEnglish
JournalInternational Angiology
Volume12
Issue number4
Pages (from-to)371-7
Number of pages7
ISSN0392-9590
Publication statusPublished - Dec 1993

    Research areas

  • Double-Blind Method, Female, Follow-Up Studies, Humans, Intermittent Claudication, Isoindoles, Male, Middle Aged, Phenylbutyrates, Platelet Aggregation Inhibitors, Time Factors

ID: 39049544